{"filing":{"accession_number":"0001193125-26-249725","cik":"0001861123","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"eikn-20260530.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm"},"events":[{"id":7771,"run_id":6821,"accession_number":"0001193125-26-249725","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"The company furnished an updated corporate presentation as a Regulation FD disclosure, which is routine investor relations material that does not constitute a material corporate event.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3101,"accession_number":"0001193125-26-249725","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a Regulation FD disclosure of an updated corporate presentation furnished as an exhibit. The filing explicitly states the information is \"furnished\" and not \"filed,\" disclaiming Section 18 liability and preventing incorporation into registration statements. This is a routine disclosure of investor relations materials that does not constitute a material event triggering any of the specific 8-K categories (no earnings, executive changes, M\u0026A, impairments, litigation, or other substantive corporate actions are disclosed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:01.681233+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":7772,"run_id":6821,"accession_number":"0001193125-26-249725","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The company announced updated clinical trial data for drug candidates EIK1001 and EIK1003 presented at ASCO 2026, which is material to investor assessment of the company's pipeline progress and regulatory prospects.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3102,"accession_number":"0001193125-26-249725","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces updated clinical trial data for two drug candidates (EIK1001 and EIK1003) presented at ASCO 2026. While clinical trial updates are material to biotech investors' assessment of pipeline progress and regulatory prospects, this does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, impairment, or litigation). The event is material because trial data directly affects investor valuation of the company's therapeutic candidates, but the taxonomy lacks a dedicated \"clinical trial results\" category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:01.681233+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3101,"accession_number":"0001193125-26-249725","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a Regulation FD disclosure of an updated corporate presentation furnished as an exhibit. The filing explicitly states the information is \"furnished\" and not \"filed,\" disclaiming Section 18 liability and preventing incorporation into registration statements. This is a routine disclosure of investor relations materials that does not constitute a material event triggering any of the specific 8-K categories (no earnings, executive changes, M\u0026A, impairments, litigation, or other substantive corporate actions are disclosed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:01.681233+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-01"},{"id":3102,"accession_number":"0001193125-26-249725","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces updated clinical trial data for two drug candidates (EIK1001 and EIK1003) presented at ASCO 2026. While clinical trial updates are material to biotech investors' assessment of pipeline progress and regulatory prospects, this does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, impairment, or litigation). The event is material because trial data directly affects investor valuation of the company's therapeutic candidates, but the taxonomy lacks a dedicated \"clinical trial results\" category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:21:01.681233+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-01"}]}